Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine bioequivalence study in AML
NCT06326697Phase 1Completed
- Sponsor
- Hikma Pharmaceuticals
- Start
- May 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azacitidine in acute myeloid leukemia (AML) (2 arms), sponsored by Hikma Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at 5 hours and Area Under the Plasma Concentration-Time Curve from Time Zero to Last Measurable Concentration at 5 hours. Started May 2024; status: completed.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06326697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06326697.